GSK · GSK
AI read · Good for GSK
The AI's read
The designation may bring tax credits and possible market exclusivity, helping GSK develop the treatment. Velzatinib is still a candidate, not an approved treatment, so the news does not show sales. The development support makes this a positive step for GSK.